Back to Search Start Over

Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation

Authors :
Maciej Tomaszewski
Prashanth Patel
Pankaj Gupta
Bryan Williams
Christobelle White
Adrian G. Stanley
Source :
Patel, P, Gupta, P K C, White, C M J, Stanley, A G, Williams, B & Tomaszewski, M 2016, ' Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation ', Journal of Human Hypertension, vol. 30, no. 6, pp. 368-73 . https://doi.org/10.1038/jhh.2015.103, https://doi.org/10.1038/jhh.2015.103, Journal of Human Hypertension
Publication Year :
2016

Abstract

Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n=34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.

Details

Language :
English
Database :
OpenAIRE
Journal :
Patel, P, Gupta, P K C, White, C M J, Stanley, A G, Williams, B & Tomaszewski, M 2016, ' Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation ', Journal of Human Hypertension, vol. 30, no. 6, pp. 368-73 . https://doi.org/10.1038/jhh.2015.103, https://doi.org/10.1038/jhh.2015.103, Journal of Human Hypertension
Accession number :
edsair.doi.dedup.....31800acd493ca9e8a81707d8363aa5c7
Full Text :
https://doi.org/10.1038/jhh.2015.103